Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;62(1):8-14.
doi: 10.1080/0284186X.2023.2175331. Epub 2023 Feb 10.

Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway

Affiliations

Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway

T E Robsahm et al. Acta Oncol. 2023 Jan.

Abstract

Background: The Prostate Cancer Cohort Consortium (PC3) Working Group proposed a definition for aggressive prostate cancer (PC) for aetiologic epidemiologic research. We aimed to validate this definition as well as a second approach utilising only information on stage at diagnosis.

Methods: First primary PCs diagnosed 2004 - 2009 in the population-based Janus Serum Bank (JSB) cohort were identified by linkage to the population-based Cancer Registry of Norway (CRN) (n = 3568). The CRN and Norwegian Prostate Cancer Registry provided clinicopathological data for these cases. Approach 1 classified PC as aggressive if it was clinically T4, or N1, or M1, or had a Gleason score ≥8 at diagnosis (as proposed). Approach 2 classified PC as aggressive if CRN stage at diagnosis was 'regional spread' or 'distant metastases'. Both approaches were validated by calculating the sensitivity and positive predictive value (PPV) against PC-death within 10 years of diagnosis.

Results: Overall, 555 died from PC within 10 years. Approach 1 classified 24.7% of cases as aggressive and 13.6% were unclassified due to missing information. Approach 2 classified 19.6% as aggressive and 29% were unclassified. Sensitivity was highest for Approach 1 (0.76, 95% CI: 0.72 - 0.80 vs 0.69, 95% CI: 0.64 - 0.73), while PPVs were similar for both approaches (0.43, 95% CI: 0.40 - 0.46 and 0.40, 95% CI: 0.36 - 0.44). We observed similarly high sensitivity and higher PPVs than those reported by the PC3 Working Group.

Conclusions: The proposed definition of aggressive PC was applicable and valid in the JSB cohort. Stage at diagnosis can be useful if data on cTNM or Gleason score is unavailable.

Keywords: Classification; aggressive prostate cancer; population-based cohort; registry data.

PubMed Disclaimer

Conflict of interest statement

Author disclosures: No conflicts of interest

Figures

Figure 1.
Figure 1.
Flowchart illustrating inclusions, exclusions, and the final study population.
Figure 2.
Figure 2.
Approaches used to classify aggressive prostate cancer (PC).
Figure 3.
Figure 3.
Sensitivity (A) and positive predictive values (B) with corresponding 95% confidence intervals for defining aggressive prostate cancer (PC) using Approaches 1 and 2 for cases diagnosed 2004–2009. The horisontal dashed lines and shaded bands represent point estimates with 95% confidence intervals for PCs diagnosed in 2007 in the SEER-18 cohort as reported by the PC3 Working Group [16].

Similar articles

References

    1. Ferlay JEM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today International Agency for Research on Cancer, Lyon, France; 2020. [Cited 2021 Jul 07 ]. Available from: https://gco.iarc.fr/today/home.
    1. Lavi A, Cohen M. [PROSTATE CANCER EARLY DETECTION USING PSA - CURRENT TRENDS AND RECENT UPDATES]. Harefuah. 2017;156(3):185–188 - PubMed
    1. Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27 - PubMed
    1. Cancer Registry of Norway. Cancer in Norway 2020 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2021.
    1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200 - PubMed

Substances